Gilead Sciences Inc SEC Filings

Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), reported a sale of 2,500 shares of Gilead common stock on 09/15/2025 at a price of $113.57 per share, reducing his beneficial holdings to 159,555 shares. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024, indicating the transaction was prearranged. The Form 4 was signed by a power of attorney on behalf of Mr. Dickinson on 09/16/2025. No derivative transactions or other types of securities are reported in this filing.

Gilead Sciences (GILD) Form 144 notice for proposed and recent insider sales. The filing shows a proposed sale of 2,500 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $283,925 and lists 1,240,806,916 shares outstanding. The filer, identified in the sales history as Andrew Dickinson, sold 2,500 shares on 06/16/2025 for $275,425, 2,500 shares on 07/15/2025 for $277,575, and 2,500 shares on 08/15/2025 for $296,325, totaling 7,500 shares sold in the past three months. Acquisition records show the securities were restricted stock acquired on 03/10/2022 (1,981 shares) and 03/10/2024 (519 shares). The filer certifies no undisclosed material adverse information and references Rule 10b5-1 language.

Gilead Sciences (GILD) Form 144 notice records a proposed sale of 3,000 common shares via Morgan Stanley Smith Barney for an aggregate market value of $340,710, with an approximate sale date of 09/15/2025 on NASDAQ. The shares were acquired as performance shares on 01/31/2024. The filing also discloses that Johanna Mercier sold 34,000 shares across three transactions in the past three months (06/16/2025, 07/15/2025, 08/15/2025) generating total gross proceeds of $3,982,524.65. The filer affirms no undisclosed material adverse information and the notice is presented as a live filing.

Daniel P. O'Day, Gilead Sciences, Inc. Chairman & CEO, reported stock award and a sale on Form 4. He received 10,427 restricted stock units (RSUs) on 09/10/2025; each RSU converts to one share and the grant follows a four-year vesting schedule with 25% vesting after one year and the remainder vesting 6.25% quarterly thereafter. The filing also shows a disposition of 4,949 shares on 09/10/2025 at a price of $115.25 per share. After these transactions the filing reports 601,203 shares beneficially owned directly and 98,496 RSUs outstanding.

Gilead Sciences insider Diane E. Wilfong, identified as Interim Corporate Controller & CAO, reported transactions on 09/10/2025. She was credited with 921 restricted stock units (RSUs) that represent rights to 921 shares subject to a four-year vesting schedule (25% at year one, then 6.25% quarterly). The filing also shows a disposition of 338 shares at a price of $115.25 each. After the transactions, Ms. Wilfong directly beneficially owns 46,259 common shares and holds 7,864 RSUs outstanding. The Form 4 is signed by power of attorney on 09/11/2025.

Deborah H. Telman, Executive Vice President, Corporate Affairs & General Counsel of Gilead Sciences (GILD), reported two transactions on 09/10/2025. She was granted 1,315 restricted stock units (RSUs), each converting to one share, which vest over four years (25% at year one, then 6.25% quarterly). The RSU grant increased contingent ownership by 1,315 shares. On the same date she disposed of 634 shares in a sale at $115.25 per share. After these transactions she beneficially owned 43,402 shares (44,036 including the unvested RSUs). The Form 4 was signed by power of attorney on her behalf.

Gilead Sciences (GILD) Form 4 filed for Johanna Mercier, Chief Commercial Officer. The filing reports on 09/10/2025 the grant of 3,844 restricted stock units (RSUs), each representing the right to one share, and the sale/disposition of 1,819 shares at $115.25 per share. After these transactions Mercier beneficially owned 116,193 shares on a direct basis. The RSUs carry a four-year vesting schedule with 25% vesting at the first anniversary and the remainder vesting quarterly at 6.25% until fully vested. The Form 4 is signed by an authorized power of attorney on behalf of the reporting person.

Gilead Sciences insider transactions by CFO Andrew D. Dickinson: The filing shows a grant of 3,696 restricted stock units (RSUs) on 09/10/2025, each convertible into one share and subject to a four-year vesting schedule (25% at one year, then 6.25% quarterly). The filing also reports a sale of 1,751 shares on 09/10/2025 at $115.25 per share. After these transactions, Mr. Dickinson beneficially owned 162,055 shares directly and had 3,696 RSUs outstanding, representing 31,219 total shares when combining vested holdings and unvested RSUs.

Daniel P. O'Day, Chairman & CEO and director of Gilead Sciences, reported a sale of 10,000 shares of GILD common stock on 08/28/2025 at a price of $113.63 per share. After the reported sale, Mr. O'Day beneficially owned 595,725 shares. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025, and the Form 4 was signed by Edward S. Son by power of attorney on 08/29/2025. The document contains no additional transactions, derivatives, or explanatory financial data beyond these disclosure items.